Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTH(1-84) vs strontium ranelate in postmenopausal osteoporosis: 24-week bone formation marker study
2006-006065-16Phase 4Completed
- Sponsor
- Takeda
- Start
- Mar 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in osteoporosis comparing PTH(1-84) (Preotact) arm with Strontium ranelate (Protelos) arm (2 arms). Primary endpoint: Change in P1NP from baseline to week 24. Started Mar 2007; status: completed.
02
Drugs
parathyroid hormone 1-84strontium ranelate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2006-006065-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006065-16.